Abstract: Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms,R.sub.2 is H or an acyl group having 1-12 carbon atoms andR.sub.3 is C, N--CH.sub.3 or a direct bond;and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non- or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favorable neuromuscular blocking agents.

Abstract: 2.beta.,16.beta.-diamino-3.alpha.,17.alpha.-oxygenated androstanes having one quaternized group, process for the preparation of these compounds and pharmaceutical compositions comprising such compounds as the active ingredient. The aforementioned compounds are favourable neuro-muscular blocking agents.

Abstract: The present invention is concerned with 11-aryloestrane and 11-arylpregnane derivatives, characterized in that these derivatives have the following structure: ##STR1## wherein R.sub.1 is an aryl group with an ##STR2## group as substituent,X and Y each being separately H or a (1-4 C) hydrocarbon radical or together a (2-6 C) hydrocarbon radical;R.sub.2 is an alkyl group containing 1-4 carbon atoms;R.sub.3 is H, OH, a saturated or unsaturated hydrocarbon radical containing 1-8 carbon atoms, at least provided with a hydroxyl, oxo, halogen, azido or nitrile group; an acyloxy or an alkoxy group;R.sub.4 is a hydroxyl, an acyloxy or an alkoxy group or an acyl group optionally provided with a hydroxyl, alkoxy, acyloxy or halogen group; or R.sub.3 and R.sub.4 together form a ring system; andR.sub.5 is a hydrocarbon group containing 1-4 carbon atoms, and further with processes for the preparation of these compounds and with pharmaceutical preparations comprising these compounds.

Abstract: Monoclonal antibodies, and hybridoma cell lines for their production, that bind with a high degree of specificity proteins associated with HTLV-III virus are presently disclosed. In particular, transmembrane envelope glycoprotein gp41 (41,000 dalton molecular size), major core antigen p24 (24,000 dalton molecular size), and p17 protein (17,000 dalton molecular size) are disclosed. The proteins to which the present monoclonal antibodies respond are essentially antigenically distinct from HTLV-I and HTLV-II. SVM-16 is an IgM monoclonal antibody, SVM-23 is an IgG.sub.2 monoclonal antibody, and SVM-26 is an IgG.sub.1 monoclonal antibody, all of which bind to p24. SVM-25 is an IgG.sub.1 monoclonal antibody binding gp41, and SVM-33 is an IgG.sub.1 monoclonal antibody binding p17. All the monoclonal antibodies of the present invention are produced in hybridoma cells prepared by fusing myeloma cells with spleen cells from mammals, such as mice, immunized with lysates of purified virus.

Abstract: The present invention is dealing with new pentasaccharides of the formula I: ##STR1## These pentasaccharides have anti-thrombotic activity and especially they possess potent anti-Xa activity, inactivate thrombin via HC-II, but do not inactivate thrombin via AT-III.The invention also refers to new tetrasaccharides which may be used as intermediates in the synthesis of the above pentasaccharides.

Abstract: A novel modified human insulin of the general formula: ##STR1## wherein R is a hydrophobic or charged amino acid or a di- or tripeptide group, comprising a hydrophobic or charged amino acid or an amide or ester of said amino acid or peptide and its use as starting material for the preparation of human insulin.

Abstract: Diluent compositions for preparing specimens for immunoassay contain effective amounts of salt and non-ionic surfactants to inactivate viruses in the specimens and improve the sensitivity and specificity of the immunoassays; said diluents having some strengths of from about 21 to about 35 mS/cm and comprising 0.05 to 1% non-ionic surfactants, along with other conventional ingredients. The invention relates as well to immunoassay procedures using the novel diluents.

Abstract: Monoclonal antibodies produced by hybridoma or transformed B-cell lines deriveed from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Abstract: Compounds of formula: ##STR1## in which R and R' each denote an alkyl or cycloalkyl radical having 1 to 7 carbon atoms; X denotes --O-- or H.sub.2 ; and Y and Z denote hydrogen or one or more radicals chosen from halogeno, hydroxy, straight or branched alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, trifluoromethyl or methylenedioxy; n being able to assume the values 2 or 3; and their pharmaceutically acceptable salts.Application as a cardiovascular medicinal product.

Abstract: Compounds of formula: ##STR1## in which R and R' denote an alkyl radical having 1 to 7 carbon atoms; R.sub.1 denotes hydrogen or an alkyl radical having 1 to 7 carbon atoms; and R.sub.2 and R.sub.3 denote, separately, an alkyl radical having 1 to 7 carbon atoms or a phenyl radical, or, together with the carbon atom to which they are attached, a cycloalkyl radical having at most 7 carbon atoms; n may assume the values 2 or 3; and their pharmaceutically acceptable salts.Application as a cardiovascular medicinal product.

Abstract: The invention relates to a pharmaceutical preparation for obtaining a highly viscose hydrogel or highly viscose suspension which is suitable to be introduced by means of an injection syringe into body cavities, and which hydrogel or suspension contains at least a drug, a polymer which is insoluble or sparingly soluble in water but has the capability of swelling in water and a watersoluble thickening agent in a relatively low quantity.

Abstract: The present invention concerns a vaccine comprising a novel canine parvovirus strain and having the property of being able to break through the maternally derived antibody levels persistent in 9-12 week old pups, and even to immunize the majority of pups at the age of 6 weeks in the presence of maternally derived antibodies.

Abstract: A novel class of steroids having pregnancy-terminating and/or pregnancy-preventing activity and a very low antiglucocorticoid activity have been found. The compounds have the general formula: ##STR1## wherein R.sub.1 and R.sub.2 each separately represent H or a (1-4 C) hydrocarbon radical or together represent a (2-6 C) hydrocarbon radical, R.sub.3 represents H or a (1-4 C) hydrocarbon radical, optionally having an OH substituent, R.sub.4 represents OH or an ester or ether group, or together with R.sub.3 represents O or a heterocyclic ring system containing O, and wherein the broken line indicates an optionally present double bond between the carbon atoms at positions 9 and 10 of the steroid skeleton.

Abstract: N,N-dimethyl-N'-benzoyl-N'-(2,3-dihydrobenzofuran-2-ylmethyl)1,3-propanedia mine of formula: ##STR1## and its pharmaceutically acceptable salts, in racemic form or in the form of enantiomers, which compounds have anti-arrhythmic properties.

Abstract: The invention relates to a method for preparing high molecular polylactic acid or copolymers of lactic acids using lactide that is purified by extraction with water.

Abstract: Vaccines containing both E.coli and herpes virus were found not to provide adequate protection against subsequent herpes virus infections. The present invention is concerned with a E.coli herpes virus combined vaccine which provides protection against both types of pathogen.

Abstract: Device for the carrying out of an immunochemical determination comprising at least one holder which is provided with an opening at the top and to the inside of which an immunochemically active substance has been applied. The device is closed at the top by a removable closure means and the holder contains at least a second immunochemically active substance which, in the absence of test medium, in the form in which the second immunochemically active substance is contained in the closed holder, during storage and transport under normal conditions exhibits no interaction with the inside of the holder and is inert with respect to the immunochemically active substance applied thereto. The holder contains a solid, more or less spherical, freeze-dried particle which contains the second immunochemically active substance.

Abstract: A solid phase immunoassay comprises the steps of(a) immobilizing an immunoreagent on the surface of a carrier comprised of an inert synthetic resin selected from the group consisting of polyimides and polyfluorinated synthetic resins,(b) contacting the immunoreagent with a complementary immunoreagent whereby an immunocomplex immobilized on said carrier is formed,(c) quantitating the immobilized immunocomplex.An element useful in conducting this solid phase immunoassay is prepared by a process of treating the surface of an article comprised of a synthetic polymer selected from the group consisting of polyimides and polyfluorinated synthetic resins to make it adsorptive of an immunoreagent which comprises the steps of(a) thoroughly rinsing the surface with a water-miscible organic solvent,(b) thoroughly rinsing the surface with water.

Abstract: An improved Schiff's reagent for detection of aldehydes (such as formaldehyde and gluteraldehyde) contains a para-rosaniline compound (such as para-rosaniline hydrochloride), orthophosphoric acid, a bisulfite compound (such as sodium metabisulfite), a phosphate compound (such as sodium orthophosphate monobasic), and water. This reagent provides lower detection levels and faster results than the reagents of the prior art, and is particularly useful in testing the rinse solutions of reusable medical equipment (such as hemodialysis equipment).

Abstract: The present invention is dealing with certain disaccharide or trisaccharide derivatives of the lipid A type, which have interesting immuno-modulating, more particularly immuno-stimulating properties.